- Home
- BILI vs EXEL Comparison
BILI vs EXEL Comparison
Compare BILI & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BILI | EXEL |
|---|---|---|
| Founded | 2009 | 1994 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.1B | 11.7B |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | BILI | EXEL |
|---|---|---|
| Price | $26.06 | $42.43 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 21 |
| Target Price | $30.00 | ★ $46.45 |
| AVG Volume (30 Days) | 2.0M | ★ 2.9M |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.95 |
| EPS | N/A | ★ 2.78 |
| Revenue | N/A | ★ $452,477,000.00 |
| Revenue This Year | $11.00 | $13.66 |
| Revenue Next Year | $8.92 | $13.73 |
| P/E Ratio | $122.37 | ★ $14.95 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.47 | $32.38 |
| 52 Week High | $36.40 | $48.74 |
Technical Indicators
Market Signals| Indicator | BILI | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 37.17 | 46.81 |
| Support Level | $25.73 | $40.01 |
| Resistance Level | $27.90 | $44.15 |
| Average True Range (ATR) | 0.77 | 1.35 |
| MACD | -0.51 | -0.22 |
| Stochastic Oscillator | 22.33 | 44.16 |
Price Performance
Historical ComparisonAbout BILI Bilibili Inc.
Bilibili is a Chinese online entertainment platform best known for its YouTube-like video-sharing site. Founded in 2009, it initially focused on long-form content centered around anime, comics, and gaming, catering primarily to Gen Z users. Over time, the platform has broadened its content offerings to include a wider range of interests, successfully attracting a more diverse audience beyond the Gen Z demographic.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.